[82] established that TET2 mutation was reported at high frequency in the following subsets of female cancers: Breast invasive carcinoma (BICA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS). The gene discussed is TET2; the disease is cervical squamous cell carcinoma.